Central Trust Company’s CareDx CDNA Stock Holding History

Central Trust Company’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6	Closed	–	–	1311
2022 Q2	$0	Hold	6	–	–	﹤0.01%	1371
2022 Q1	$0	Buy	+6	New	+$234	﹤0.01%	1358

Other funds holding CDNA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Central Trust Company's CDNA Position: Q3 2022 in Review

Central Trust Company sold out of CareDx (CDNA) in Q3 2022, closing a stake of 6 shares.

Central Trust Company first reported a position in CDNA in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 182 funds tracked by Wall St. Rank hold CDNA as of Q3 2022.

Central Trust Company reported no remaining CareDx position as of Q3 2022 after selling out during the quarter.
Central Trust Company sold 6 CareDx shares in Q3 2022.
Central Trust Company first reported a position in CareDx in Q1 2022 and held it in 2 quarters.
Central Trust Company's CareDx position peaked at $0 in Q2 2022.
182 funds tracked by Wall St. Rank held CareDx as of Q3 2022.

Based on Central Trust Company's 13F filing for Q3 2022, filed 3 Nov 2022.